Research & Development

Cancer Research UK, LifeArc, Ono Pharma establish new drug discovery alliance

Cancer Research UK has entered into a multi-year partnership with LifeArc and Ono Pharmaceutical to identify new immunotherapy drug targets for cancer.

MedPharm to develop new XF-drug formulations

Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF‐platform compounds.

Transgene, BioInvent extend collaboration to develop multifunctional oncolytic viruses for solid tumors

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB, a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.

Arch Oncology raises $50m Series B financing

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing.

Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn

Thermo Fisher Scientific has agreed to acquire viral vector contract development and manufacturing organization (CDMO), Brammer Bio, for around $1.7bn in cash.

Imago BioSciences announces $40m Series B financing led by Omega Funds

Imago BioSciences, a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, has announced a $40 million Series B financing led by Omega Funds, an international investment firm that creates and invests in life sciences companies.

Merck, NGM Bio extend multi-year strategic collaboration

Merck and NGM Biopharmaceuticals announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022.

Pfizer secures option to buy Vivet Therapeutics in €560m deal

US pharmaceutical company Pfizer has secured an exclusive option to acquire gene therapy firm Vivet Therapeutics in a deal that could be valued at around €560m ($635.8m).

Evotec, GARDP partner to tackle antimicrobial resistance threat

German biotech company Evotec has entered into a partnership with The Global Antibiotic Research and Development Partnership (GARDP) to discover antibiotics for the treatment of drug-resistant bacterial infections.